ANTIFUNGAL AGENTS

Ilona Benkő M.D., Ph.D.

Fungal infections – MYCOSES

Superficial Systemic

DermatomycosesCandidiasis

Trichophyton

Malassesia furfur

Microsporum

Epidermophyton

Candidiasis

Candida albicans

Candida tropicalis

Candida kruzei

Aspergillosis

Aspergillus nidulans

Subcutan mycoses

Sporothrix schenkii

Histoplasmosis Blastomycosis

Coccidioidomycosis

Paracoccidioidomycosis

The underlined the opportunistic pathogens

Risk Factors for fungal diseases

Broad-spectrum antibacterial therapy

Reduced immune responses (phagocytosis, neutropenia, T4 ly, Th-1 cytokines)

Primary and secondary immundeficient syndromes


AIDS

Immunosuppressant drug therapy, transplantation

Cancer chemotherapy

Malignant hematological diseases

Diabetes mellitus Local factors Intravenous or urogenital canules



Discovery of antifungal drugs **Table 47.2**

Decade	Drug			
1950s	Amphotericin			
1960s	Griseofulvin			
1970s	Flucytosine, clotrimazole, miconazole			
1980s	Ketoconazole, fluconazole, itraconazole			
1990s	Terbinafine, naftifine, different formulations ^a of amphotericin			
2000s	Caspofungin			
Under development	Voriconazole ^b , posaconazol ^b , ravuconazole ^b , micafungin (FK463) ^b , sordarins, pradimicin, nikkimycin			

^aDifferent formulations: liposomes, nanosomes, nanoparticles.

bUndergoing clinical trials.

Application

Superficial infections



oral

tabl, caps

suspension

Topical Ointment

Solution Nail lacquer

Powder

Eye/ear drop Vaginal tablets

Systemic infections




oral tabl, caps

parenteral infusion, injection

special formulations:


liposomes

1. Polyene antifungal drugs from Streptomyces speciei, macrolide antibiotics I.



mechanism of action:

binding to ergosterol – pore formation! in the membranes



Katzung et al Basic and Clinical Pharmacology textbook

1. Polyene antifungal drugs from Streptomyces speciei, macrolide antibiotics II.

amphotericin B

resistance: RARE! change in ergosterol content

combined with 5-FC

Pharmacokinetics:

Poorly absorbable, lipid soluble drug

Complexed with sodium deoxycholate

New formules:

Complexed with b-cyclodextrin or lipids

Encapsuled in liposomes or nanospheres (long-circulating)

Very slow elimination, excretion by kidney

Side effects


Renal toxicity
Myelotoxicity
Hypokalemia
Impaired hepatic function
Anaphylactic reactions
Chills, fever, tinnitus, haedache, vomitus - intrathecal injection neurotoxicity

nystatine

nd plasma!

Nystatine is stable in dry form but decomposes quickly in the presence of water and plasma!

Orally against intestinal Candida infections, NO ABSORPTION from mucous membranes and skin (no significant blood or tissue level)



Drug	Physical Form	Dosing (mg/kg/d)	C _{max}	Clearance	Nephrotoxicity	Infusional Toxicity	Daily Cost (\$)
Conventional f	ormulation		nii olaistata Kan kanka		coment of patients w		
Fungizone	Micelles	opent sistem	able Union	din nivgar	d hide wenter ou	depubende	24
Lipid formulati	ons						
AmBisome	Spheres	3-5	1	. ↓ annon		1	1300
Amphotec	Disks	5	1	1		↑(?)	660
Abelcet	Ribbons	5	↓	1		↓(?)	570

2. flucytosine, 5-fluorocytosine

synthetic converted to 5-FU by fungal deaminase

resistance: change in deaminase

Pharmacokinetics:

Water-soluble
Widely distribution, into CNS too
Half-life: 3-5 hours
Excretion via kidney

Side effects

Myelosuppression, alopecia, hepatitis, gastrointestinal





Figure 57-2 Action of fluortocine in funci Di-



Rang and Dale's Pharmacology, textbook

3. AZOLES



synthetic broad spectrum

mech. of action:

inhibition of P450 3A (CYP 3A) dependent lanosine 14alfa-demethylase

imidazoles


triazoles: specificity better, fluconazole water soluble, crosses blood-brain barrier

Toxicity:

liver, fulminant hepatitis, GI, pruritus imidazoles block adrenocortical steroid and testosteron synthesis – gynecomastia


drug interactions:

terfenadine, astemizole, ciclosporine H2 receptor blocking drugs decrease ketoconazole's absorption



3. AZOLES

imidazoles



triazoles

	Water Solubility	Absorption	CSF: Serum Concentration Ratio	t _{1/2} (Hours)	Elimination	Formulations
Ketoconazole	Low	Variable	< 0.1	7–10	Hepatic	Oral
Itraconazole	Low	Variable	< 0.01	24-42	Hepatic	Oral, IV
Fluconazole	High	High	> 0.7	22-31	Renal	Oral, IV
Voriconazole	High	High	indicki samuri samuri sat Marin San "San San San San San San San San San San	6	Hepatic	Oral, IV
Posaconazole	Low	High		25	Hepatic	Oral

4. Echinocandins


caspofungin a ring of 6 amino acids linked to lipophilic side chain

mech. of action:

Inhibition of the synthesis of beta-glucan, a polymer which is necessary for maintaining the structure of fungal cell wall

invasive aspergillosis:

amphotericin B itraconazole voriconazole caspofungin



5. Griseofulvin

from *Penicillium griseofulvum* narrow spectrum

It concentrates in skin, nails, hair - orally but only for superficial infections !!!

mech. of action:

binds to microtubules and inhibits mitosis

Pharmacokinetics

poorly water solubility and variable absorption

Toxicity

Neurotoxicity, haedache, gastrointestinal upsets, photosensitivity

6. Allilamines

terbinafine

allilamines: terbinafine (Lamisil)

mech. of action: inhibition of squalen-epoxidase

Pharmacokinetics:

orally good absorption, high concentrations in fat, skin, nail, hair metabolism in liver

7. Thiocarbamates

tolnaphtate (Chinofungin)

mech. of action: inhibition of squalen-epoxidase

against dermatophytons


8. Morpholins

amorolfin (Loceryl)

mech. of action: inhibition of 14 reductase and 7-8 izomerase

enzimes

THE MECHANISM OF ACTION OF TERBINAFINE



Vatacanarala	I Placks fungal DAFO on	Doorly coloctive - in	Broad spectrum but toxicity re-	Oral, topical • Toxicity and inter-
• Ketoconazole	Blocks fungal P450 en- zymes and interferes with ergosterol syn- thesis	Poorly selective • in- terferes with mam- malian P450 function	stricts use to topical therapy	actions: Interferes with steroid hormone synthesis and phase I drug metabolism
• Itraconazole	Same as for ketocona- zole	Much more selective than ketoconazole	Broad spectrum: Candida, Crypto- coccus, blastomycosis, coccidio- idomycosis, histoplasmosis	• poor entry into central nervous system (CNS) • Toxicity and interactions: Low toxicity
· Fluconazole, voricon	azole, posaconazole: Fluconazo	le has excellent CNS pene	tration, used in fungal meningitis	
The second of the second	ctore, antiviral assertion	e elefectiock	Europial del Condide en eleguard	I Wanks direction 11 15 h
Caspofungin Caspofunging Caspofunging	Blocks β-glucan syn- thase	Prevents synthesis of fungal cell wall	Fungicidal Candida sp • also used in aspergillosis	IV only • duration, 11–15 h • <i>Toxicity:</i> Minor gastrointestinal effects, flushing • <i>Interac</i> -
	e with host cell literation	and result in	Cytochronic P450	tions: Increases cyclosporine levels (avoid combination)
	funain: Micafunain increases lev	rels of nifedipine, cyclospo	rine, sirolimus; anidulafungin is relative	ly free of this interaction
· Micafungin, anidula	Sa la la sentimenta de la Massacción	morate dispunsal		
· Micafungin, anidula ALLYLAMINE	ior anticancer diseases.	Congress of the congress of th		

Treatment of superficial infections:

For TOPICAL use

antiseptics	Polyene	azoles	allylamines	others
	macrolides		and	
			thiocarbamates	
salicylic acide	nystatine	ketoconazole	Allylamine:	morpholine:
iodine,	natamycine	clotrimazole	terbinafine	amorolfine
hexachlorophe	candicidine	miconazole	naftifine	-
ne,		econazole	thiocarbamate:	cyclopyrox
metals		bifonazole	tolnaphtate	olamine
		oxiconazole		undecylenic
				acid

Orally

azoles	polyenes	griseofulvin
ketoconazole	nystatine	
fluconazole	Only for GI infections !!	It concentrates in skin,
voriconazole	No absorption	nails, hair

Treatment of systemic infections

polyenes	nucleotide	azoles	echinocandins
amphotericin B	5-fluorocytosine	ketoconazole	caspofungin
Liposomal		itraconazole	micafungin
amphotericine B		fluconazole	cilofungin
_		voriconazole	

invasive aspergillosis:

amphotericin B itraconazole voriconazole caspofungin

(A) Ergosterol biosynthesis I.

